RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic <i>EGFR</i> -mutated NSCLC

Kazumi Nishino, Takashi Seto, Makoto Nishio, Kazuto Nishio, Kazuo Kasahara, Miyako Satouchi, Kiyotaka Yoh, Hidetoshi Hayashi, Sotaro Enatsu, Tomoko Matsui, Sunoj Chacko Varughese, Carla Visseren-Grul, Kazuhiko Nakagawa

Open source

DOI: 10.1080/14796694.2025.2560225
Published: 2025-09-25
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2560225,
  title = {RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic
                    <i>EGFR</i>
                    -mutated NSCLC},
  author = {Kazumi Nishino and Takashi Seto and Makoto Nishio and Kazuto Nishio and Kazuo Kasahara and Miyako Satouchi and Kiyotaka Yoh and Hidetoshi Hayashi and Sotaro Enatsu and Tomoko Matsui and Sunoj Chacko Varughese and Carla Visseren-Grul and Kazuhiko Nakagawa},
  year = {2025},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2025.2560225},
  url = {https://doi.org/10.1080/14796694.2025.2560225}
}

RIS

TY  - JOUR
TI  - RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic
                    <i>EGFR</i>
                    -mutated NSCLC
AU  - Kazumi Nishino
AU  - Takashi Seto
AU  - Makoto Nishio
AU  - Kazuto Nishio
AU  - Kazuo Kasahara
AU  - Miyako Satouchi
AU  - Kiyotaka Yoh
AU  - Hidetoshi Hayashi
AU  - Sotaro Enatsu
AU  - Tomoko Matsui
AU  - Sunoj Chacko Varughese
AU  - Carla Visseren-Grul
AU  - Kazuhiko Nakagawa
PY  - 2025
JO  - Future Oncology
DO  - 10.1080/14796694.2025.2560225
UR  - https://doi.org/10.1080/14796694.2025.2560225
ER  -

APA

Nishino, K., Seto, T., Nishio, M., Nishio, K., Kasahara, K., Satouchi, M., Yoh, K., Hayashi, H., Enatsu, S., Matsui, T., Varughese, S. C., Visseren-Grul, C., & Nakagawa, K. (2025). RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic <i>EGFR</i> -mutated NSCLC. Future Oncology. https://doi.org/10.1080/14796694.2025.2560225

Source records

crossref · retrieved 2026-09-26T01:30:31.435Z